PTSM: Pharmaceutical Technology Sourcing and Management
SGS Life Sciences expands chemistry and microbiology testing services after acquisition of Quality Compliance Laboratories.
SGS, a bio/pharmaceutical analytical and bioanalytical contract solutions provider, announced on Jan. 19, 2016 that after the acquisition of Quality Compliance Laboratories (QCL) in December 2015, its global network now offers chemistry and microbiology testing services for cosmeceuticals, natural health products, and medical marijuana from facilities in Canada.
According to the company, since the acquisition of QCL, SGS has incorporated all 65 employees from QCL’s Canadian sites into SGS’s global network of laboratories. The facilities in Montreal and Markham, Toronto, have a combined laboratory space of more than 10,000 sq. ft. There are plans to equip the Markham site with new walk-in stability chambers. The facilities are GMP compliant and are licensed/registered with, and inspected by, both Health Canada and FDA.
New capabilities within the two facilities include a inductively coupled plasma-mass spectrometer and inductively coupled plasma-optical emission spectrometer for elemental impurities analysis, fully automated tablet dissolution apparatuses, flow-through USP dissolution apparatus, and Vitek for bacterial identification. Alongside the company’s existing facility in Mississauga, Canada, SGS has a service provision of analytical testing for pharmaceutical and biopharmaceutical products, raw materials and packaging, and medical devices capacity throughout Canada.
With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I–IV clinical trial management, and services encompassing data management and statistics, Pharmacokinetic/Pharmacodynamic modeling and simulation, pharmacovigilance, and regulatory consultancy.
Source: SGS Life Science Services
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.